I call attention to this paper of mine just published in Eye & Contact Lens together with colleagues Drs. Kathryn Richdale, Erin Tomiyama and Mark Bullimore – a survey of the variability of atropine formulation, sterility and stability testing and storage requirements for compounded low dose atropine for myopia prevention.
Dr. Gary Novack is a board-certified clinical pharmacologist and President of PharmaLogic Development with more than 40 years of experience in ophthalmic drug development, clinical research, and FDA regulatory strategy.
He has consulted for over 100 pharmaceutical and medical device companies and authored more than 400 scientific publications.